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Abstract: Prototheca sp. can assume high economic significance in the dairy industry 
and pose a potential risk for the public health. Studies on the susceptibility of Prototheca spp. 
to antimicrobials have demonstrated its high level of resistance. We investigated the in vitro 
susceptibility of ten Prototheca zopfii isolates retrieved from mastitic milk and one P. 
wickerhamii referent strain, from American Type Collection using MIC Test Strip. P. zopfii 
isolats showed susceptibility to MIC between 1,5-4 µg/mL for ketoconazole, and between 
1,5-3 µg/mL for amphotericin B. In contrast P. wickerhamii strain prouved to be efficient to a 
MIC of 2 µg/mL in case of ketoconazole and 0,75 µg/mL for amphotericin B. Both species 
tested  showed to be resistant to itraconazole.This study demonstrates different in vitro 
susceptibility patterns of P. wickerhamii and P. zopfii, reinforcing the necessity for more 
investigation into drugs that can be used with clinical efficacy. 
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INTRODUCTION 
 
Prototheca spp. are unicellular, achlorophylic, nonphotosynthetic algae, globally 
ubiquitous, and readily isolated from rivers, lakes, ponds, and soil (Huerre 1993). Typical 
sources of Prototheca species are
 
the slime flux of trees, grass, fresh and salt water, 
wastewater,
 
animals such as cattle, deer, and dogs, stables, animal buildings,
 
excrement (Pore 
et al., 1983; Pore , 1986), and food such as butter, potato
 
peels, cow's milk, soil, and bananas 
(Pore, 1985; Pore, 1986).Currently P. zopfii, P. wickerhamii, P. stagnora, P. ulmea, P. 
blaschkeae have been recognized.  
They are opportunistic pathogen for humans and animals. Although canine and bovine 
protothecosis have been reported more widely, infections in humans are rare, particularly in 
patients with an intact immune system (Woolrich et al, 1994). The majority of protothecal 
infections in humans is associated with Prototheca wickerhamii, while in animals with P. 
zopfii (Casal, 1981; Follador et al, 2001; Jensen et al., 1998; Lass-Flörl et al., 2004; Leimann 
et al, 2004). 
Treatment of protothecal infections remains controversal, and
 
various treatment 
regimens have been attempted, but there has
 
been no consistency in the clinical responses 
(Lass-Flörl et al., 2004) 
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This paper aimed to investigated the antimicrobial activity of ketoconazole, 
itraconazole and amphotericin B against two Prototheca species, as well as to found the most 
efficient antifungal agent used in treating of protothecosis. 
 
MATERIALS AND METHODS 
 
In vitro antimicrobial susceptibility of ten Prototheca zopfii. isolates and one P. 
wickerhamii referent strain was measured using minimal inhibitory concentration  (MIC) Test 
Strip. The isolates were identified on the basis of the presence of daughter cells and on 
biochemical features (assimilation of glucose, galactose, glycerol, sucrose and trehalose, and 
growth at 28 and 37ºC). Three antifungal were evaluated: ketoconazole, itraconazole and 
amphotericin B.  
MIC Test Strips is a quantitative assay for determining the Minimum Inhibitory 
Concentration of antimicrobial agents against microorganisms to indicate appropriate patient 
treatment and for identifying resistance patterns. When the MIC Test Strip is applied onto an 
inoculated agar surface, the preformed exponential gradient of antimicrobial agent was 
transferred into the agar matrix. After 24-48 hours incubation or longer, a symmetrical 
inhibition ellipse centered along the strip was formed. The MIC was read directly from the 
scale in terms of µg/mL, at the point where the edge of the inhibition ellipse intersects with 
the MIC Test Strip. 
 
RESULTS AND DISCUSSION 
 
Tests carried out in order to establishing the antimcrobials effect of antifungal agents 
showed different aspects according to the drugs and to the species of Prototheca tested  
Table 1 summarizes the in vitro susceptibility profile of Prototheca species to 
antifungal egent evaluated.  
 
Tab. 1 
In vitro susceptibility profile of two Prototheca species to antifungal tested 
 
 
ISOLATES TESTED 
ANTIFUNGAL TESTED 
Ketoconazole 
MIC (µg/ml) 
Itraconazole 
MIC (µg/ml) 
Amphotericin B 
MIC (µg/ml) 
 
 
 
 
P. zopfii 
1 2 R 1,5 
2 3 R 3 
3 4 R 2 
7 4 R 1,5 
11 4 R 2 
14 2 R 1,5 
16 1,5 R 1,5 
17 4 R 2 
18 4 R 3 
20 3 R 2 
P. wickerhamii 2 R 0,75 
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All the P. zopfii tested isolates prouved to be susceptible to ketoconazole (with the 
MIC between 1,5 µg/ml – 4 µg/ml) and to amphotericin B (MIC between 1,5 µg/ml – 4 
µg/ml). In case of P. wickerhamii ketoconazole prouved to be efficient to a MIC of 2 µg/ml, 
while amphotericin B to a MIC of 0,75 µg/ml. Both species tested were resistant to 
itraconazole. 
A graphic representation of the MIC for antifungal agent used, for both Prototheca 
species tested is depicted in the fig. no. 5. 
Our research performed in order to test the in vitro eficiency of some antifungal 
products demonstrated that ketoconazole and amphotericin B can be used in protothecosis 
therapy. The main feature of minimim inhibitory concentration for the antifungal tested, is 
their low value, that could to be an advantage if the use of products in protothecosis therapy. 
Although our date reveal the in vitro effectiveness of antifungal tested, in vivo studies 
should be carried out. 
Fig. 1, P. zopfii (2 isolates) - the 
efficiency of ketoconazole to a MIC of 3 
Fig. 2, P. wickerhamii - the efficiency 
of ketoconazole to a MIC of 2 
Fig. 3, P. zopfii (1 isolates) - the 
efficiency of Amphotricin B to a MIC 
of 1,5 µg/ml 
Fig. 4, P. wickerhamii - the efficiency 
of amphotericin B to a MIC of 0,75 
µg/ml 
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Fig. 5. The efficiency of antifungal agent tested (MIC) form both Prototheca species tested 
 
CONCLUSIONS 
 
 From all the products tested ketoconazole (MIC 1,5 µg/ml – 4 µg/ml) and amphotericin B 
(MIC 0,75 µg/ml - 4 µg/ml) were efficient for both Protoheca species tested. 
 Both Prototheca species were resistant to itraconazole. 
 Although our study reveal the efficiency of ketoconazole and amphotericin B, furthere 
research will be done in order to evaluated in vivo efficiency of those products. 
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